Prevention of genomic instability by a scavenger of bifunctional electrophiles
双功能亲电试剂清除剂预防基因组不稳定性
基本信息
- 批准号:9186510
- 负责人:
- 金额:$ 20.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-01 至 2019-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenineAldehydesAllelesAminationAminesAnimalsBacteriaBarrett EsophagusCancer cell lineCarcinogensCell NucleusCellsCessation of lifeColon CarcinomaCopy Number PolymorphismCysteineDNADNA AdductsDNA Modification ProcessDevelopmentEpigenetic ProcessEvaluationEventFVB MouseGenetic RecombinationGenomic InstabilityGenomicsGenotypeHistologyHistonesHumanHydrogenIsomerismKRAS2 geneLesionLipid PeroxidationLipid PeroxidesLipoxygenaseLungLysineMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMalondialdehydeMammalian CellMediatingMetabolismMouse StrainsMusMutagensMutationN-methylacetamide-oxotremorine MNatureNuclearNucleic AcidsNucleoproteinsNucleosidesOncogenicOxidantsPTGS2 genePatientsPenetrancePeriodicityPositioning AttributePost-Translational Protein ProcessingPremalignantPreventionProcessProstaglandin-Endoperoxide SynthaseProstaglandinsProtein IsoformsProteinsRattusResearchSeriesSiteStructureSystemTestingThromboxane A2Thromboxanesadductanalogbaseclinically significantcrosslinkcyclooxygenase 2cytotoxicearly onsethistone modificationin vivoketoaldehydemacromoleculemalignant breast neoplasmmalignant phenotypemouse modeloxidationpreventpublic health relevancetooltumor
项目摘要
DESCRIPTION (provided by applicant): Progression from pre-malignant lesions to clinically significant cancers involves acquisition of somatic genomic abnormalities that in concert drive the development of cancers with a highly malignant phenotype. Reactive dicarbonyls derived from cyclooxygenase-2 (COX-2), the lipoxygenases and lipid peroxidation are known to form covalent adducts of DNA and histones. It is proposed to address the hypothesis that these modifications of DNA and histones contribute to the somatic genomic abnormalities that characterize cancers. The immediate product of both COX isoforms is the cyclic endoperoxide, prostaglandin H2 (PGH2), the substrate for the synthases that produce the prostaglandins and thromboxane A2. PGH2 also undergoes non-catalytic rearrangement to form the levuglandins, highly reactive γ-ketoaldehydes. In cancer cell lines, we have demonstrated that COX-2 derived levuglandins form covalent adducts of DNA and histones. Our group has investigated a series of scavengers of levuglandins that react with these 1,4-dicarbonyls at a rate 3 orders of magnitude faster than does lysine, thereby inhibiting the formation of the levuglandin adducts of cellular amines on DNA bases and on histones. We have identified one, 5-ethylsalicylamine that is potent in preventing levuglandin adducts of lysine, does not inhibit COX-2 and acts in the cellular nucleus. Importantly, we discovered that 5-ethylsalicylamine is a general scavenger of reactive dicarbonyls, including malondialdehyde and 4-oxo-nonenal, both of which also form covalent adducts of DNA. To evaluate the hypothesis that these reactive dicarbonyls are endogenous carcinogens, we will determine the effects of 5- ethylsalicylamine on the development of the somatic genomic abnormalities that occur in a mouse with lung expression of a Kras mutation that produces lung cancers which progressively develop genomic instability with extensive copy number variations. Copy number variations will be determined with the Mouse Diversity Genotyping Array. The effect of 5-ethylsalicylamine on tumor size and histology also will be evaluated as well as its effect on the levels of levuglandin and malondialdehyde adducts of DNA and histones in the tumors. In summary, a number of reactive dicarbonyls, exemplified by the levuglandins, malondialdehyde and 4-oxo- nonenal, are produced by COX-2, lipid peroxidation and the lipoxygenases and can form covalent adducts of DNA and histone, suggesting that they could be endogenous carcinogens. It is hypothesized that 5- ethylsalicylamine, a scavenger of these dicarbonyls, will prevent the genomic instability that occurs in a mouse model of lung cancer.
描述(由申请人提供):从癌前病变进展到临床显著的癌症包括获得体细胞基因组异常,这些异常共同推动具有高度恶性表型的癌症的发展。由环氧合酶-2(COX-2)衍生的反应性二羰基、脂氧合酶和脂质过氧化已知形成DNA和组蛋白的共价加合物。有人建议解决这样的假设,即DNA和组蛋白的这些修饰导致了体细胞基因组异常,这种异常是癌症的特征。这两种COX亚型的直接产物是环状内过氧化前列腺素H2(PGH2),它是产生前列腺素和血栓素A2的合成酶的底物。PGH2还经历非催化重排形成左旋糖素,即高活性的γ-酮醛。在癌细胞系中,我们已经证明了COX-2衍生的左旋糖素形成DNA和组蛋白的共价加合物。我们的团队研究了一系列左旋糖素的清除剂,它们与这些1,4-二羰基的反应速度比赖氨酸快3个数量级,从而抑制了DNA碱基和组蛋白上细胞胺的左旋糖素加合物的形成。我们已经确定了一种5-乙基水杨胺,它有效地阻止了左旋糖苷赖氨酸的加合物,不抑制COX-2,并作用于细胞核。重要的是,我们发现5-乙基水杨胺是反应性二羰基的一般清除剂,包括丙二醛和4-氧-壬烯醛,这两种物质也形成DNA的共价加合物。为了评估这些反应性二羰基是内源性致癌物的假设,我们将确定5-乙基水杨胺对发生在肺表达Kras突变的小鼠身上的体细胞基因组异常的发展的影响,该突变产生肺癌,肺癌逐渐发展为具有广泛拷贝数变化的基因组不稳定。拷贝数变异将通过小鼠多样性基因分型阵列来确定。还将评估5-乙基水杨胺对肿瘤大小和组织学的影响,以及对肿瘤中DNA和组蛋白的左旋糖苷和丙二醛加合物水平的影响。综上所述,由COX-2、脂质过氧化和脂氧合酶产生的以左旋腺苷、丙二醛和4-氧基-壬烯醛为代表的一些反应性二羰基可以形成DNA和组蛋白的共价加合物,这表明它们可能是内源性致癌物质。据推测,5-乙基水杨胺,这些二羰基的清除剂,将防止在小鼠肺癌模型中发生的基因组不稳定。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN Alexander OATES其他文献
JOHN Alexander OATES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN Alexander OATES', 18)}}的其他基金
Prevention of COX-2 Derived DNA and Histone Modifications in Cancer
预防癌症中 COX-2 衍生的 DNA 和组蛋白修饰
- 批准号:
9248194 - 财政年份:2015
- 资助金额:
$ 20.4万 - 项目类别:
Prevention of COX-2 Derived DNA and Histone Modifications in Cancer
预防癌症中 COX-2 衍生的 DNA 和组蛋白修饰
- 批准号:
9017969 - 财政年份:2015
- 资助金额:
$ 20.4万 - 项目类别:
Development of Compounds for the Prevention and Treatment of Rhabdomyolysis
预防和治疗横纹肌溶解症的化合物的开发
- 批准号:
8834621 - 财政年份:2014
- 资助金额:
$ 20.4万 - 项目类别:
Lipid Modification of Proteins by the PGH Synthases
PGH 合成酶对蛋白质进行脂质修饰
- 批准号:
7929873 - 财政年份:2009
- 资助金额:
$ 20.4万 - 项目类别:
SCCOR in Hemostatic and Thrombotic Diseases
SCCOR 在止血和血栓性疾病中的应用
- 批准号:
7808876 - 财政年份:2006
- 资助金额:
$ 20.4万 - 项目类别:
SCCOR in Hemostatic and Thrombotic Diseases
SCCOR 在止血和血栓性疾病中的应用
- 批准号:
7622651 - 财政年份:2006
- 资助金额:
$ 20.4万 - 项目类别:
THE PHARMACOLOGY OF INHIBITORS OF HEME PROTEIN-CATALYZED LIPID PEROXIDATION
血红素蛋白催化脂质过氧化抑制剂的药理学
- 批准号:
7209628 - 财政年份:2006
- 资助金额:
$ 20.4万 - 项目类别:
相似海外基金
The Role of Adenine Nucleotide Translocase in Mitochondrial Dysfunction Associated Senescence in Chronic Obstructive Pulmonary Disease (COPD)
腺嘌呤核苷酸转位酶在慢性阻塞性肺病(COPD)线粒体功能相关衰老中的作用
- 批准号:
10633608 - 财政年份:2023
- 资助金额:
$ 20.4万 - 项目类别:
Pathways of Succinate Accumulation and Adenine Nucleotide Depletion in Cardiac Ischemia
心脏缺血中琥珀酸积累和腺嘌呤核苷酸消耗的途径
- 批准号:
10794933 - 财政年份:2022
- 资助金额:
$ 20.4万 - 项目类别:
Pathways of Succinate Accumulation and Adenine Nucleotide Depletion in Cardiac Ischemia
心脏缺血中琥珀酸积累和腺嘌呤核苷酸消耗的途径
- 批准号:
10534031 - 财政年份:2022
- 资助金额:
$ 20.4万 - 项目类别:
Development of nobel assay methods for miRNA and adenine methyltransferase using FRET
使用 FRET 开发 miRNA 和腺嘌呤甲基转移酶的诺贝尔检测方法
- 批准号:
21K05120 - 财政年份:2021
- 资助金额:
$ 20.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Critical assessment of DNA adenine methylation in brain cells from healthy aging and Alzheimer's disease
健康老龄化和阿尔茨海默病脑细胞 DNA 腺嘌呤甲基化的批判性评估
- 批准号:
10365337 - 财政年份:2021
- 资助金额:
$ 20.4万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10033546 - 财政年份:2020
- 资助金额:
$ 20.4万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10613902 - 财政年份:2020
- 资助金额:
$ 20.4万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10226235 - 财政年份:2020
- 资助金额:
$ 20.4万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10396102 - 财政年份:2020
- 资助金额:
$ 20.4万 - 项目类别:
DNA Methylation at N6-Adenine in Placental Trophoblast Development
胎盘滋养层发育中 N6-腺嘌呤 DNA 甲基化
- 批准号:
10705982 - 财政年份:2020
- 资助金额:
$ 20.4万 - 项目类别: